君实生物
TopAlliance

**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.***
**上海君實生物醫藥科技股份有限公司**
*(a joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock code: 1877)**

# SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Reference is made to the annual report of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") for the year ended 31 December 2021, which was published on 29 April 2022 (the "**2021 Annual Report**"). Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the 2021 Annual Report.

## SUPPLEMENTAL INFORMATION TO THE 2021 ANNUAL REPORT IN RELATION TO THE USE OF THE NET PROCEEDS FROM THE H SHARE LISTING AND THE LISTING ON THE STAR MARKET

In addition to the information provided in the 2021 Annual Report, the Board would like to provide further information under the section headed "7. Global Offering, Listing on the STAR Market and Use of Proceeds" in the Management Discussion and Analysis on pages 43 to 45 of the 2021 Annual Report as follows:

### H Share Listing

| **Planned Usage** | **Unutilized proceeds as at 31 December 2020**<br>*RMB'000* | **Proceeds utilized during the Reporting Period**<br>*RMB'000* |
|---|---|---|
| The R&D and commercialization of the Group's drug candidates | 102,659 | 91,776 |
| *The R&D and commercialization of the Group's Core Product, JS001* | 44,155 | 39,708 |
| *The R&D of the Group's other drug candidates to fund clinical trials worldwide, including JS004, etc.* | 47,082 | 40,646 |

| Planned Usage | Unutilized proceeds as at 31 December 2020 *RMB'000* | Proceeds utilized during the Reporting Period *RMB'000* |
|---|---|---|
| *The construction of, acquisition of facilities for and settlement of start-up costs on the Lingang Site and the Wujiang Site* | 11,422 | 11,422 |
| The Group's investment in the health care and/or life science sector(s), including acquisition of companies, licensing-in and collaboration | 4,571 | 4,000 |
| The Group's working capital and other general corporate purposes | 71 | 25 |
| Total | 107,301 | 95,801 |

**Listing on the STAR Market**

| Committed investment projects | Unutilized proceeds as at 31 December 2020 *RMB'000* | Proceeds utilized during the Reporting Period *RMB'000* |
|---|---|---|
| Research and development projects of innovative drugs | 725,220 | 615,038 |
| Junshi Biotech Industrialization Lingang Project | – | – |
| Repayment of bank loans and replenishment of liquidity | 270,733 | 254,763 |
| Surplus proceeds | 1,434,739 | 190,447 |
| Total | 2,430,692 | 1,060,248 |

## SUPPLEMENTAL INFORMATION TO THE 2021 ANNUAL REPORT IN RELATION TO THE USE OF THE NET PROCEEDS FROM THE PLACING OF H SHARES UNDER GENERAL MANDATE

In addition to the information provided in the 2021 Annual Report, the Board would like to provide further information under the section headed "Placing of H Shares Under General Mandate" in the Report of the Directors on page 146 of the 2021 Annual Report as follows:

| Purpose of the proceeds | Intended use of the net proceeds *(Approx. RMB million)* | Proceeds utilized during the Reporting Period *(Approx. RMB million)* | Unutilized proceeds as at 31 December 2021 *(Approx. RMB million)* | Expected timeline for application of the unutilized proceeds |
|---|---|---|---|---|
| R&D of drugs and pipeline expansion | 815 | 596 | 219 | Expected to be fully utilized by 30 June 2025 |

| Purpose of the proceeds | Intended use of the net proceeds *(Approx. RMB million)* | Proceeds utilized during the Reporting Period *(Approx. RMB million)* | Unutilized proceeds as at 31 December 2021 *(Approx. RMB million)* | Expected timeline for application of the unutilized proceeds |
|---|---|---|---|---|
| Expansion of the commercialization team | 1 | – | 1 | Expected to be fully utilized by 30 June 2025 |
| Domestic and overseas investment, mergers and acquisitions & business development | 285 | 61 | 224 | Expected to be fully utilized by 30 June 2022 |
| General corporate purpose | 1,003 | 754 | 230 | Expected to be fully utilized by 30 June 2025 |
| | 2,104*(Notes 1 and 2)* | 1,411*(Note 1)* | 674*(Note 1)* | |

*Notes:*

1. The difference between (i) the sum of proceeds utilized and unutilized proceeds and (ii) the net proceeds from the Placing represents foreign exchange losses and interests generated from bank saving accounts.

2. The difference between the net cash inflow from the Placing and the net proceeds available for use by the Group represents payables for transaction costs of the Placing amounting to approximately RMB0.8 million.

The information contained in this supplemental announcement does not affect other information contained in the 2021 Annual Report. Save as disclosed above, all other information in the 2021 Annual Report remains unchanged.

By order of the Board
**Shanghai Junshi Biosciences Co., Ltd.***
**Mr. Xiong Jun**
*Chairman*

Shanghai, the PRC, 27 September 2022

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.*

* *For identification purpose only*